News|Articles|November 15, 2018

Pharmaceutical Technology

  • Pharmaceutical Technology-11-15-2018
  • Volume 2018 eBook
  • Issue 2

Complex Protein Studies Demand Dynamic Techniques

By adapting techniques from other sciences-and exploring better tools for biologics drug development-researchers are addressing challenges of protein characterization.

Proteins must be characterized at many phases of biopharmaceutical research, development, and manufacturing, each with differing demands and requirements. Instrument capabilities-and limitations-influence the speed and success of development efforts. Researchers from biopharma, contract service organizations, and academia face challenges of selecting and optimizing appropriate techniques for protein characterization needs.

Experts interviewed by Pharmaceutical Technology shared similar concerns about the need to conduct complex protein characterization studies under the pressures of tight timelines and urgency to get new drug products to clinic and approval.

Read this article in Pharmaceutical Technology's Bio/Pharma Laboratory Best Practices 2018 eBook.

Article Details

Pharmaceutical Technology
eBook: Bio/Pharma Laboratory Best Practices 2018
Vol. 42
November 2018
Pages: 42–46

Citation

When referring to this article, please cite it as R. Peters, "Complex Protein Studies Demand Dynamic Techniques," Pharmaceutical Technology Bio/Pharma Laboratory Best Practices eBook (November 2018).

 

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.